Data on Perifosine in the Treatment of Patients with Relapsed/Refractory
Multiple Myeloma to be presented on Saturday, December 8th at 5:30pm
NEW YORK, Dec. 7 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that abstracts related to KRX-0401 (Perifosine) have been selected for presentation during the poster sessions scheduled to take place at the upcoming American Society Hematology Meeting and exposition taking place at the Georgia World Congress Center in Atlanta, Georgia (December 8-11, 2007).
Copies of these abstracts, which highlight the observed clinical activity of KRX-0401 in the treatment of patients with relapsed/refractory multiple myeloma are currently available and can be viewed on-line through the ASH website: http://www.abstracts2view.com/hem07/
The following abstracts will be presented on Saturday, December 8, 2007 at 5:30pm:
 - Board #318-I
Multi-Center Phase II Study of Perifosine (KRX-0401) Alone and in Combination with Dexamethasone (dex) for Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Promising Activity as Combination Therapy with Manageable Toxicity.
Paul Richardson, S. Lonial, A. Jakubowiak, A. Krishnan, J. Wolf, J. Densmore, S. Singhal, I. Ghobrial, J. Stephenson, J. Mehta, K. Colson, D. Francis, T. Kendall, N. Obadike, K. Sullivan, J. Martin, T. Hideshima, L. Lai, P. Sportelli, L. Gardner, R. Birch, I.C. Henderson, K. Anderson
 - Board #323-I
A Multiple Myeloma Research Consortium (MMRC) Multicenter Phase I Trial
of Perifosine (KRX-0401) in Combination with Lenalidomide and Dexamethasone
|SOURCE Keryx Biopharmaceuticals, Inc.|
Copyright©2007 PR Newswire.
All rights reserved